MN Pharmaceuticals is one of the leading and oldest pharmaceutical companies in Turkey. The company was established in 1923 in a district of İstanbul known as Üsküdar, İhsaniye under the name of Mustafa Nevzat Laboratory.
Its founder Prof. Mustafa Nevzat Pisak played an important role in establishing contemporary pharmacy in Turkey, in changing the academic pharmacy program to one fashioned on Western methods, and in the development of Turkish Pharmaceutical Industry.
His "Laboratory" is one of the first manufacturers of injectable ampoules in Turkey. With its 8 employees, the laboratory moved to another district, Divanyolu, and then to Nuruosmaniye in 1933.
In 1957 it moved to Mecidiyeköy and became a joint stock company. In 1984, in addition to the plant in Mecidiyeköy, the Yenibosna facilities were established. The plant in Mecidiyeköy, in turn, has moved to its present location at Yenibosna in 2003.
Currently, with its trained personnel of 1000 and modern facilities, MN Pharmaceuticals is one of the leading manufacturers of bulk pharmaceutical chemicals and finished dosage forms.
At API Facility, active pharmaceutical ingredients such as clarithromycin and clarithromycin granules for suspension, sulbactam sodium, sultamicillin tosylate and sultamicillinbase are currently produced.
All basic forms of pharmaceuticals, such as ampoules, vials, freeze-dried injectables, capsules, plain and coated tablets and dry powder suspensions are produced by MN Pharmaceuticals in its three separate manufacturing plants in Istanbul.
With its high-capacity injectable units and lyophilization facilities, MN Pharmaceuticals is Turkey's most experienced pharmaceutical company in parenteral drug manufacturing.
Penicillin and cephalosporin-like beta-lactam products are produced in two separate, dedicated plants.
In a separate and dedicated third plant, other groups of antibiotics, corticosteroids, cardiovascular preparations, antiinflammatory agents, gastrointestinal agents and products of other therapeutic classes are manufactured.
The products are manufactured according to "Current Good Manufacturing Practices (cGMP)" and "Current Good Laboratory Practices (cGLP)" and as a result of continuous training, education and modern technology are offered to human health care both in Turkey and in various countries abroad.
MN Pharmaceuticals received EU-GMP certificate from Germany for the ampicillin sodium / sulbactam sodium for injection in July 2004.
MN Pharmaceuticals signed strategic partnership agreements with several leading US generic companies for marketing and sales of its products and has submitted the first ANDA file to FDA in 2005. This is also a “first” for Turkish Pharmaceutical Industry. By taking the initial step in exporting finished dosage forms to the US, MN Pharmaceuticals has paved the way for the other Turkish pharmaceutical companies to follow.
Our API and finished dosage forms facilities has been inspected by FDA in November 2006. As a result of FDA inspection, MN Pharmaceuticals is the first Turkish Pharma Company which has been granted an FDA approval for the API and finished dosage forms.
The pharmaceutical products of MN Pharmaceuticals are registered in and exported to Afghanistan, Albania, Algeria, Azerbaijan, Bosnia & Herzegovina, Czech Republic, Georgia, Germany, Kingdom of Saudi Arabia, Kosovo, Malaysia, Malta, Pakistan, Philippines, Republic of Kazakhstan, Republic of Macedonia, Republic of Uzbekistan, Russian Federation, Turkish Republic of Northern Cyprus, USA, Venezuela, Vietnam and Yemen.
Prof. Mustafa Nevzat's professional aim of always accomplishing the best and his great respect for human welfare are still the basic principles of MN Pharmaceuticals.